Interview with Mahesh P. Karande, Head of the Africa Cluster for Novartis. In this role, he is responsible for leading Novartis business activities in sub-Saharan Africa.
How Novartis is working towards the elimination of leprosy across the world with partners such as the World Health Organization (WHO) by donating multidrug therapy (MDT) to treat leprosy patients globally.
Novartis runs an annual program to support independent eye care initiatives worldwide via grant funding, including some in the world’s most remote areas and deprived communities.
Novartis is investing in thermal energy storage to minimize fuel costs and reduce the carbon footprint of new buildings.
Martin Edlund is a founding member and CEO of Malaria No More. During his tenure, he has implemented high-profile engagement campaigns leveraging cutting edge mobile, social, and e-commerce platforms. Prior to Malaria No More, Martin was a journalist and political consultant.
Up the stairs to the entrance of the plane they climb: small children with cloudy eyes, teens with thick glasses and practiced squints, adults with dark shades.
Novartis has helped fight the disease by donating multidrug therapy (MDT) to leprosy patients worldwide through the World Health Organization.
Limited resources and other barriers have long stymied advances in medical research infrastructure in Africa. But the situation is starting to change. Many countries are making greater investments in science as part of broader efforts to tackle local health problems.
Novartis' Arogya Parivar initiative is a pioneering business approach which aims to deliver healthcare sustainably to more people, particularly in the developing world.
Novartis is proud to have achieved Silver Class status in this year’s edition of the RobecoSAM “Sustainability Yearbook” for our excellent sustainability performance.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.